Premium
Effects of interferon‐gamma and tumor necrosis factor‐alpha on clonogenic growth of cell lines and primary cultures from human gliomas and brain metastases
Author(s) -
HELSETH EIRIK,
TORP SVERRE,
DALEN ARE,
UNSGAARD GEIRMUND
Publication year - 1989
Publication title -
apmis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 88
eISSN - 1600-0463
pISSN - 0903-4641
DOI - 10.1111/j.1699-0463.1989.tb00832.x
Subject(s) - clonogenic assay , tumor necrosis factor alpha , interferon gamma , in vitro , glioma , medicine , alpha (finance) , alpha interferon , cancer research , cell culture , cytokine , necrosis , interferon , immunology , pharmacology , pathology , biology , surgery , biochemistry , construct validity , genetics , patient satisfaction
In this study we tested the effect of interferon‐gamma (IFN‐gamma), tumor necrosis factor‐alpha (TNF‐alpha) and a combination of these immunotherapeutics on clonogenic growth of cell lines and primary cultures of malignant human brain tumors. Out of 29 primary cultures studied, 5 were inhibited 50% or more by IFN‐gamma (10 ng/ml), 6 were inhibited 50% or more by TNF‐alpha (10 ng/ml) and 14 were inhibited 50% or more by a combination of IFN‐gamma (10 ng/ml) and TNF‐alpha (10 ng/ml). The doses of the immunotherapeutics used in this in vitro study are achievable in serum after intravenous administration of IFN‐gamma and TNF‐alpha without causing unacceptable side effects. We believe that some glioma patients and some patients with brain metastases will benefit from receiving treatment with IFN‐gamma, TNF‐alpha or a combination of these immunotherapeutics. The patients should be selected for treatment with these immunotherapeutics according to in vitro sensitivity results.